Dr. Charles Lynde

Dermatologist, Markham, ON

Dr. Charles Lynde is an Associate Professor in the Department of Medicine at the University of Toronto and holds a clinical teaching position at the University Health Network. He is the Medical Director of Lynde Institute for Dermatology and Lynderm Research. The Lynde Institute for Dermatology is a full service, interdisciplinary dermatology clinic. After receiving his B.Sc. and MD, degrees at the University of Toronto, Dr. Lynde studied Dermatology at the University of British Columbia and the University of Toronto, receiving his Board Certification (Canada and USA) in 1983.

Lynderm Research is under the guidance of Dr. Lynde as principal investigator for more than 30 years and over 300 clinical trials and is actively involved in the management of psoriasis, rosacea, onychomycosis, acne and atopic dermatitis among other dermatological conditions. Dr. Lynde has authored over 200 peer-reviewed articles.

Dr. Lynde has served in various roles for the CDA and AAD, including President of the Canadian Dermatology Association. He is the Editor of the CDA eBulletin and sits on the editorial boards of several journals and provides extensive consulting as well as being on the advisory boards of many pharmaceutical companies. Dr. Lynde is a frequent guest speaker both nationally and internationally at various dermatological conferences. Recognizing the need for external education he is committed to the training of new and current healthcare professionals in his community and residents through the university program.

Plenary Session 1: 10:10 AM - 10:15 AM

NOV 2 (Thu)

Welcome Message

Plenary Session 1: 11:15 AM - 11:25 AM

NOV 2 (Thu)

Q & A

2:35 PM - 3:25 PM

NOV 2 (Thu)

Diagnostic & Therapeutic Pearls

In this session, we will be discussing many new treatments that are becoming available, or are being actively studied, for use in the dermatology space for conditions such as pyoderma gangrenosum and generalized pustular psoriasis.

Plenary Session 2: 10:05 AM - 10:55 AM

NOV 3 (Fri)

Drug Update

Immunology continues to touch all of our lives as dermatologists. The research and development pipeline remains exciting into the year 2023. We have moved beyond the large-scale “biologics era” in psoriasis and atopic dermatitis. 2022-2023 (and beyond) was the year of the big “biosimilar switch”.

We are seeing the development of increasingly “fine tuned” molecules for these conditions, with some exciting new launches in Canada within the past year. JAK Inhibitors have officially been prescribed in our practices for two years now in atopic dermatitis. We now have good “real world” experience with these molecules. We are looking forward to the potential launches of JAK Inhibitors in the areas of alopecia areata and vitiligo soon.

Conditions such as vitiligo, alopecia areata, hidradenitis suppurativa, prurigo nodularis have shifted into the focus for much of the new dermatology pharmaceutical industry research and development.

We are seeing unique molecules focusing on the microbiome or with unique methods of delivery. This presentation will provide an overview on what dermatology drugs are new to the market, the status of current clinical trials and an overview of the current landscape in dermatology drug development.

Plenary Session 2: 10:55 AM - 11:15 AM

NOV 3 (Fri)

New and Emerging Therapies for Vitiligo

New and Emerging therapies for vitiligo will involve updating dermatologists on the impacts on well-being and mental health, looking at new JAKI and other immune-based treatments. We will also update you on ways to address melanocyte pathology using phototherapy, excimer laser, and new melanocyte-focused treatments.

Plenary Session 2: 11:15 AM - 11:25 AM

NOV 3 (Fri)

Q & A

2:00 PM - 2:40 PM

NOV 3 (Fri)

Managing Pain for in-clinic dermatology and aesthetic procedures

The standard of care in managing pain for short-term dermatology and aesthetic procedures is well established. However, there is a new paradigm for pain management for in-clinic dermatology and aesthetic procedures that you may not yet know.

Objectives:

  1. Discuss the pros and cons of treatment options of pain management of short-term in-clinic dermatology and aesthetic procedures
  2. Educate and share clinical experience on the efficacy and safety of inhaled analgesic for in-clinic dermatology and aestshetic procedures

4:30 PM - 5:00 PM

NOV 3 (Fri)

Challenges in Treating Skin Reactions in Oncology Patients Receiving Targeted Therapy

The aim of the CaSMO group is to address challenges in treating skin reactions in oncology patients receiving cancer therapies by developing practical clinical tools. These tools aim to support all healthcare providers treating oncology patients and survivors, including physicians, nurses, pharmacists, and advanced providers.

In this 30-minute presentation, Maxwell Sauder will address recommended CaSMO approaches to four targeted therapy-related cutaneous adverse events: 1) Papulopustular eruptions, 2) xerosis, 3) Paronychia, 4) Hand and foot skin reaction.

11:25 AM - 12:15 PM

NOV 4 (Sat)

Southern Exposure: Clascoterone real-world experience in the U.S

Session objectives:
After attending this program, attendees will be able to:

  1. Understand and describe the clascoterone phase 3 and extension trial data, and how it can be applied to the Canadian acne treatment landscape
  2. Gain perspective and understanding into the real-world treatment of acne with clascoterone based on U.S. experience

Session description:
With the evolving acne treatment landscape and the recent Health Canada approval of acne therapy clascoterone, there remains a need for clinical discussions around the real-world use of current acne treatments. In this session, Dr. Todd Plott will provide insight into the experience of treating acne in the United States, including the use of clascoterone, through presentation and case discussion. The session will conclude with an opportunity for the audience to pose questions to Dr. Plott.

Plenary Session 3: 3:30 PM - 3:45 PM

NOV 4 (Sat)

Closing Comments